The cost the hospital never sees: half of families spend more than 15% of their income
also called financial toxicity pediatric leukemia · ACCL20N1CD · family out-of-pocket cost leukemia
In a study of 104 US parents whose child had just been diagnosed with leukemia, half were spending more than 15% of the household's monthly income on it, and six in ten had cut back on groceries. Nearly six in ten were paying for care through Medicaid or CHIP, which means the families affected are disproportionately poor before the diagnosis arrives.
The same thing, for a scientist
Children's Oncology Group study ACCL20N1CD surveyed 104 parents of children with newly diagnosed ALL during induction across 28 COG practices in the NCI Community Oncology Research Program. Financial burden exceeded 15% of monthly gross household income for 51.5%, 43% reported high financial distress, 59.6% cut back on groceries and 58.7% on other necessities, and 57.7% were paying with Medicaid or CHIP. Poverty-level income, Medicaid/CHIP coverage, unemployment and living in a socioeconomically disadvantaged area all independently predicted high distress. These are baseline-survey data from induction, the very beginning of a multi-year course.
The measured burden, at induction2 deeper
Denominator: 104 parents of children with newly diagnosed ALL, surveyed during induction, across 28 US COG practices 1.
| Measure | Proportion |
|---|---|
| Financial burden >15% of monthly gross household income | 51.5% |
| High financial distress (score 1-4) | 43% |
| Cut back on groceries | 59.6% |
| Cut back on other necessities | 58.7% |
| Paying with Medicaid or CHIP | 57.7% |
Independent predictors of high distress were poverty-level income (p=0.0009), Medicaid or CHIP coverage (OR 3.0, 95% CI 1.26-7.13), unemployment (OR 2.5, 1.1-5.7) and living where more than half of residents have socioeconomic disadvantages (OR 3.0, 1.13-8.05) 1.
The authors note these coping behaviours have health implications: a family cutting back on groceries during a child's induction is a family whose child's nutritional status and adherence are at risk.
Why this belongs in a platform-economics beat
Three consequences follow directly.
- Payer mix. If 57.7% of these families are on Medicaid or CHIP, then the majority payer for a US infant leukemia drug is a state Medicaid programme subject to statutory rebates, not a commercial plan. That structurally caps net realised price on a paediatric-only asset and is part of why paediatric-only development is commercially unattractive (see
platform-counterargument-adult-commercial-gravity). - Trial participation. Travel to an Interfant or COG centre, extended parental leave and accommodation are borne by families already cutting back on groceries. Financial toxicity is an enrolment barrier in a population where, in Australia, there are only about five eligible infants a year to begin with (
epi-infant-leukemia-uk-and-australia). Any trial design that adds visits adds an equity problem. - The direction of a 'saving'. An oral outpatient drug that reduces inpatient days genuinely helps this family, and that benefit never appears in a hospital cost analysis. It is a real argument for the platform that is currently going unmade because nobody measures it.
Caveats worth stating twice
This is a baseline survey during induction, so it captures the acute shock, not the two-year course or the survivorship years. It is ALL of all ages, not infants specifically; infants require a parent present continuously and so the true infant burden is almost certainly worse. The sample of 104 is small and drawn from community oncology practices, which may under-represent families who travel to a distant academic centre.
A systematic review across ten countries found out-of-pocket costs of US$16-$2,523 per month per patient or caregiver, and loss of income or productivity affecting 14-57.8% of patients and families, so the COG findings sit inside a broad international pattern rather than being an American artefact 2.
| cohort n | 104 |
|---|---|
| practices | 28 |
| financial burden over 15pct income | 51.5 |
| high financial distress PCT | 43 |
| cut back groceries PCT | 59.6 |
| cut back other necessities PCT | 58.7 |
| medicaid or chip PCT | 57.7 |
| population | parents of children with newly diagnosed ALL, induction |
international oop range usd per month
[ 16, 2523 ]
- A Medicaid-dominated payer mix caps net price on a paediatric-only asset. That is not a moral failing of any company, it is a structural fact, and any strategy that assumes an infant-first commercial launch has to answer it explicitly.
- Trial designs that add visits, imaging or serial marrows push cost onto families who are already cutting back on food, and the resulting non-participation will be recorded as 'declined consent' rather than as an economic barrier.
- What is the financial burden specifically on families of infants, who require continuous parental presence for a two-year protocol and often relocate to a transplant centre?
- Does an oral outpatient targeted agent measurably reduce family out-of-pocket and productivity costs relative to inpatient chemotherapy, and has anyone tried to measure it?
- Given that most of these families are on Medicaid or CHIP, what is the actual net price a state pays for a paediatric menin inhibitor course after statutory rebate?
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Among 104 parents of children with newly diagnosed ALL surveyed during induction across 28 US COG practices, financial burden exceeded 15% of monthly gross household income for 51.5%, 43% reported high financial distress, 59.6% cut back on groceries, 58.7% on other necessities, and 57.7% paid with Medicaid or CHIP; poverty-level income, Medicaid/CHIP, unemployment and neighbourhood disadvantage predicted high distress.
Baseline Characteristics of Parents Enrolled in Children's Oncology Group Study ACCL20N1CD: Financial Toxicity During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States · Santacroce SJ, Beauchemin MP, Ponce O, et al. · Pediatric Blood & Cancer 2025What this evidence cannot show
Baseline cross-sectional survey of 104 self-selected, English- or Spanish-speaking parents during induction only; community oncology practices, so referral-centre families may be under-represented; paediatric ALL of all ages with no infant stratum reported.
Evidence that argues against this (2)
- The 15%-of-income threshold is an imported adult metric and may be measuring the wrong thing in a paediatric population. A group-concept-mapping study with 80 stakeholders -- parents, caregivers, childhood cancer survivors and clinical and non-clinical support personnel -- across 41 countries, 78% of them low- and middle-income, found that existing methods for assessing financial hardship are 'heterogeneous and designed using high-income country (HIC), adult perspectives', and derived a six-cluster framework (medical, non-medical, assistance and support, treatment impact, family impact, caregiver impact) that the authors describe as distinct in composition from the existing adult-oncology framework. Caregiver impact (mean 3.39) and treatment impact (mean 3.29) were rated the highest-impact clusters, and impact ratings were higher in LMICs than HICs. The ACCL20N1CD instrument measures medical and material burden well and the two highest-rated clusters least well. Abstract read via PubMed; full text not read. Ritter J et al. 2024
- Whether the hardship is attributable to the cancer is genuinely disputed within the best-powered cohort available. In the Childhood Cancer Survivor Study, Nathan and colleagues (3,555 survivors, 956 siblings, surveyed 2017-2019) found survivors significantly more likely than siblings to report hardship on at least one of 21 items (63.4% vs 53.7%, p<0.001) and higher in all three domains; Fair and colleagues, in an earlier CCSS analysis of 698 survivors and 210 siblings, found that 'the intensity of financial hardship did not significantly differ between survivors and siblings' and that insurance status rather than cancer history dominated. This entry's ACCL20N1CD baseline survey has no sibling or general-population comparator at all, so it cannot distinguish the burden of childhood leukaemia from the baseline burden of being a poor family in the US health system -- which its own finding that 57.7% were on Medicaid or CHIP makes the live alternative explanation. Both abstracts read via PubMed; neither full text read. Nathan PC et al. 2022
- E2moderate confidence 3 of 5: One strong study, or several smaller consistent ones.review
A systematic review of 18 studies across ten countries found out-of-pocket costs of US$16 to US$2,523 per month per patient or caregiver following a cancer diagnosis, and loss of income or productivity affecting 14% to 57.8%.
The economic impact of cancer diagnosis to individuals and their families: a systematic review · Alzehr A, Hulme C, Spencer A, Morgan-Trimmer S · Supportive Care in Cancer 2022What this evidence cannot show
Adult cancer patients aged 18 and over, all tumour types, costs converted to 2019 US dollars by purchasing power parity across very heterogeneous health systems. It does not cover paediatric cancer and the wide range reflects methodological heterogeneity as much as real variation.
Evidence that argues against this (1)
- A directly paediatric replacement for this adult systematic review's role in the entry, with a contrary emphasis: the Fair 2021 CCSS analysis found that in 698 childhood-cancer survivors versus 210 siblings the intensity of financial hardship did not differ significantly overall, and that health insurance was protective across behavioural (OR 0.12, 95% CI 0.06-0.22), material (OR 0.37, 95% CI 0.19-0.71) and psychological (OR 0.10, 95% CI 0.05-0.21) domains. If insurance rather than diagnosis is the dominant modifiable factor, the policy implication for infant leukaemia in the US is coverage continuity rather than out-of-pocket caps, which is a different intervention from the one this entry's framing implies. Jurisdiction US. Abstract read via PubMed; full text not read. Fair D et al. 2021
Counter-evidence and internal dispute (Nathan 2022, PMID 36179267 vs Fair 2021, PMID 34061973): two analyses of the same Childhood Cancer Survivor Study disagree on whether survivors bear excess financial hardship relative to siblings -- 63.4% vs 53.7% (p<0.001, n=3,555) against 'no significant difference' (n=698), with insurance status the dominant protective factor in the latter. Childhood-cancer-specific economic data exist; they are contested and they stop short of infancy.
Counter-evidence (Ritter 2024, PMID 39208390): existing financial-hardship instruments are explicitly 'designed using high-income country (HIC), adult perspectives', and a stakeholder-derived childhood-cancer framework differs in composition, rating caregiver impact and treatment impact highest -- the two clusters the ACCL20N1CD 15%-of-income metric measures least well. The ACCL20N1CD survey also has no sibling comparator, so it cannot separate cancer burden from baseline poverty (57.7% Medicaid/CHIP).
costs the hospital ledger does not record
caregiver burden concentrated around transplant